Expression of CD276 in ccRCC specimens is correlated with adverse clinicopathologic outcomes (tumor size, tumor stage, nuclear grading, coagulative tumor necrosis, and sarcomatoid differentiation). This evidence concerns the gene CD276 and neoplasm.